Afinitor 5 mg Alternative – XeviroI (Everolimus) 5 mg Tablet | Beacon Pharmaceuticals
XeviroI 5 mg (Everolimus) Tablet by Beacon Pharmaceuticals. Reference brand: Afinitor. mTOR inhibitor; used in selected breast, kidney and neuroendocrine cancers. Prescription medicine. Brand comparison does not establish interchangeability.
Product Overview
XeviroI 5 mg Tablet is listed in the supplied Beacon Pharmaceuticals anti-cancer and hematology price list. The stated active ingredient is Everolimus. Afinitor is a reference brand for the generic ingredient. This is a product-identification comparison, not a claim of verified bioequivalence or interchangeability.
XeviroI vs Afinitor – Reference Brand Comparison
Afinitor is a recognized reference brand associated with Everolimus. XeviroI is listed under Beacon Pharmaceuticals. Their excipients, marketing authorizations, formulation details and regulatory evidence may differ. A clinician or pharmacist must confirm whether substitution is appropriate.
Composition and Active Ingredient
Brand: XeviroI. Active ingredient: Everolimus. Strength: 5 mg. Dosage form: Tablet. Therapeutic class: mTOR inhibitor. Listed manufacturer: Beacon Pharmaceuticals Ltd., Bangladesh. Packaging details should be confirmed on the manufacturer’s current pack.
Therapeutic Uses and Indications
Everolimus is used in selected breast, kidney and neuroendocrine cancers. These are generic-level clinical contexts and do not independently confirm every indication for this particular branded presentation. Eligibility may depend on biomarkers, previous therapy and country-specific labeling.
Mechanism of Action – How Everolimus Works
Everolimus inhibits mTOR signaling. This mechanism alone does not establish suitability or effectiveness for an individual patient.
Dosage and Administration
The 5 mg shown is the strength of this tablet, not a recommended daily dose. Dose, timing, food instructions and treatment duration must be determined by the treating specialist using the current authorized prescribing information. Do not change dose or substitute brands or strengths without medical approval.
Contraindications
Contraindications depend on Everolimus, formulation and individual medical conditions. Review the current official prescribing information, particularly hypersensitivity, pregnancy-related and organ-function restrictions.
Warnings and Precautions
Important safety considerations include mouth sores, infections and pneumonitis. The prescriber may require laboratory testing, cardiac or organ-function assessment, and ongoing monitoring.
Possible Side Effects
Potential adverse effects and serious reactions include mouth sores, infections and pneumonitis. Other reactions can occur. Consult the product leaflet for the full adverse-effect profile and seek medical care for severe symptoms.
Drug Interactions
Drug interactions may affect treatment effectiveness or toxicity. Inform the treating clinician of all prescriptions, over-the-counter products, herbal supplements and other treatments.
Pregnancy, Fertility and Breastfeeding
Some oncology and hematology medicines can cause fetal harm and require specific contraception or breastfeeding restrictions. Follow the medicine-specific official labeling and specialist advice.
Storage and Handling
Store according to the instructions printed on the actual Beacon Pharmaceuticals pack. Protect from inappropriate heat, humidity and light, and keep out of reach of children. Do not assume the storage conditions of another brand apply.
Why Is XeviroI Listed as an Alternative to Afinitor?
The comparison helps identify another listed brand containing Everolimus. It does not establish identical formulation, regulatory approval, bioequivalence or permission to substitute.
Manufacturer Information
Listed brand: XeviroI. Manufacturer: Beacon Pharmaceuticals Ltd., Bangladesh. Reference brand: Afinitor. Generic: Everolimus. Strength: 5 mg. Dosage form: Tablet.
Frequently Asked Questions
What is XeviroI 5 mg? It is a tablet containing Everolimus 5 mg according to the supplied Beacon price list. What is it used for? Everolimus is used in selected breast, kidney and neuroendocrine cancers, subject to specialist assessment. Can it replace Afinitor? Not automatically; a qualified professional must check product-specific equivalence and regulatory requirements. Is a prescription required? Yes, appropriate prescription and specialist supervision are necessary.
Important Medical Disclaimer
This listing is for educational pharmaceutical identification only and is not a substitute for medical advice, official product labeling or regulatory review. Brand, strength and pack details should be confirmed against the current manufacturer information before dispensing.
| Generic Name | Everolimus |
|---|---|
| Strength | 5 mg |
| Manufacturer | Beacon Pharmaceuticals Ltd. |
Related products
Balversa 4 mg Alternative – Erdarixen (Erdafitinib) 4 mg Tablet | Everest Pharmaceuticals
Erdarixen 4 mg (Erdafitinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Balversa (Janssen). It belongs to the FGFR inhibitor class and is used in selected FGFR-altered urothelial cancer.
Active ingredient: Erdafitinib
Strength: 4 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Cometriq 20 mg Alternative – Caboxen (Cabozantinib) 20 mg Capsule | Everest Pharmaceuticals
Caboxen 20 mg (Cabozantinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Cometriq (Exelixis). It belongs to the multikinase inhibitor class and is used in selected medullary thyroid cancer settings for capsule formulations; other cabozantinib formulations have different approved uses.
Active ingredient: Cabozantinib
Strength: 20 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Gleevec / Glivec 100 mg Alternative – Imaxen (Imatinib) 100 mg Tablet | Everest Pharmaceuticals
Imaxen 100 mg (Imatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Gleevec / Glivec (Novartis). It belongs to the BCR-ABL/KIT/PDGFR kinase inhibitor class and is used in selected chronic myeloid leukemia and gastrointestinal stromal tumor settings.
Active ingredient: Imatinib
Strength: 100 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Kisqali 200 mg Alternative – Riboxen (Ribociclib) 200 mg Tablet | Everest Pharmaceuticals
Riboxen 200 mg (Ribociclib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Kisqali (Novartis). It belongs to the CDK4/6 inhibitor class and is used in selected HR-positive, HER2-negative breast cancer regimens.
Active ingredient: Ribociclib
Strength: 200 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Megace 160 mg Alternative – Mezoxia (Megestrol acetate) 160 mg Tablet | Everest Pharmaceuticals
Mezoxia 160 mg (Megestrol acetate) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Megace (Bristol Myers Squibb). It belongs to the progestin class and is used in certain hormone-responsive cancer settings depending on formulation and jurisdiction.
Active ingredient: Megestrol acetate
Strength: 160 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Promacta / Revolade 25 mg Alternative – Elopag (Eltrombopag) 25 mg Tablet | Everest Pharmaceuticals
Elopag 25 mg (Eltrombopag) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Promacta / Revolade (Novartis). It belongs to the thrombopoietin receptor agonist class and is used in selected immune thrombocytopenia and aplastic anemia settings.
Active ingredient: Eltrombopag
Strength: 25 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Zejula 100 mg Alternative – Niranib (Niraparib) 100 mg Capsule | Everest Pharmaceuticals
Niranib 100 mg (Niraparib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Zejula (GSK). It belongs to the PARP inhibitor class and is used in selected ovarian cancer maintenance treatment settings.
Active ingredient: Niraparib
Strength: 100 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Zytiga 250 mg Alternative – Abiraxen (Abiraterone acetate) 250 mg Tablet | Everest Pharmaceuticals
Abiraxen 250 mg (Abiraterone acetate) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Zytiga (Janssen). It belongs to the androgen biosynthesis inhibitor class and is used in selected advanced prostate cancer regimens with corticosteroid therapy.
Active ingredient: Abiraterone acetate
Strength: 250 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.

Reviews
There are no reviews yet.